LLY Eli Lilly and Company
Company Analysis
Latest News
Eli Lilly Opens Early Access to Retatrutide for Severe Obesity Patients
Eli Lilly established an expanded access program for its experimental obesity drug, retatrutide, ahead of potential FDA approval. This program provides the...
Eli Lilly and Company Q2 2026 Earnings Preview: What Analysts Expect on August 05, 2026
Analysts expect Eli Lilly to report Q2 2026 consensus revenue of $20.65 billion and EPS of $6.71, with the current stock price of $1,121.36 sitting below the...
Eli Lilly's Cancer Drug Olomorasib Gets FDA Breakthrough Therapy Tag for Pancreatic Cancer
Eli Lilly and Company announced its experimental drug, olomorasib, received Breakthrough Therapy designation from the U.S. Food and Drug Administration (FDA)....
🔴 Eli Lilly is trading 3% down today on profit-taking after a multi-month rally and sector volatility
Eli Lilly is trading 3% down at $1114.17 on profit-taking and consolidation following a strong multi-month rally and recent sector-wide volatility. • The move...
🔴 Eli Lilly is trading 3.4% down today as managed care weakness weighs on sector sentiment
Eli Lilly is trading 3.4% down at $1,165.73 as managed care weakness drags the broader healthcare sector lower. • The move occurs without fresh...
Eli Lilly and Resilience to Invest $750 Million in U.S. Manufacturing Expansion
Eli Lilly and Company, with contract manufacturer Resilience, announced a $750 million investment. This investment will expand pharmaceutical production in the...
Eli Lilly Retatrutide Succeeds in Phase 3, Showing 22.6% Weight Loss
Eli Lilly and Company reported positive topline results from its TRIUMPH-2 and TRIUMPH-3 Phase 3 trials for retatrutide. The investigational weight-loss drug...
Novo Nordisk sues Eli Lilly, alleging false ads for Zepbound and Mounjaro
Novo Nordisk filed a lawsuit in U.S. federal court against Eli Lilly for false and misleading advertising. The complaint targets marketing for Lilly’s...
Eli Lilly's Foundayo prescriptions jump to 24,303, defying broader market slump
Weekly prescriptions for Eli Lilly’s oral obesity drug Foundayo reached 24,303. This figure breaks a five-week plateau where prescriptions remained near...
Eli Lilly in Advanced Talks to Acquire Psychedelic Drugmaker AtaiBeckley
Eli Lilly & Co. reportedly holds advanced discussions to acquire psychedelic drug developer AtaiBeckley. A deal announcement could occur as soon as this week....
Novo Nordisk wins EU approval for oral Wegovy, first GLP-1 pill
The European Commission approved Novo Nordisk’s once-daily oral version of Wegovy. This is the first oral GLP-1 treatment for weight management in the European...
Eli Lilly’s Retevmo Wins Full FDA Approval for Advanced Solid Tumors
The U.S. Food and Drug Administration granted full approval to Eli Lilly’s Retevmo on Tuesday for treating advanced solid tumors. The approval applies to adult...
🔴 Eli Lilly is trading 3% down today as CVS Health questions GLP-1 cost-effectiveness
Eli Lilly is trading 3% down at $1146.36 after CVS Health’s pharmacy benefits arm raised concerns over the return on investment for expensive GLP-1 weight-loss...
US Appeals Court Revives Teva Lawsuit Against Eli Lilly Over Forteo
A U.S. appeals court revived a lawsuit from Teva Pharmaceuticals. Teva accuses Eli Lilly of breaching a settlement related to the osteoporosis drug Forteo. The...
Eli Lilly Receives $1,400 Price Target, Fueled by Mounjaro and Zepbound
JPMorgan analyst Chris Schott raised the Eli Lilly price target to $1,400. The previous target was $1,300. Schott reiterated an Overweight rating for the...
Eli Lilly to Unveil New Alzheimer's Data for Donanemab and Advanced Diagnostics at AAIC 2026
Eli Lilly and Company will present 16 research abstracts at the Alzheimer's Association International Conference (AAIC). The conference runs from July 12-15 in...
Lilly's Double Catalyst — Can a $50 Obesity Pill and a Cancer Drug Expansion Justify a Trillion-Dollar Valuation?
Shares of Eli Lilly surged 3.7% to $1,244.16 after two developments landed in quick succession: European regulators endorsed a broader use for the company's...
🟢 LLY is trading 3.7% up today after Medicare pricing deal and Jaypirca label expansion
LLY is trading 3.7% up at $1244.16 following positive regulatory and reimbursement developments for its core drug portfolio. • An EMA panel recommended a...
Eli Lilly eyes $71M Foundayo debut, betting on easier dosing than Wegovy
Jefferies analysts forecast Eli Lilly’s new oral obesity drug, Foundayo, will generate $71 million in U.S. sales for its debut quarter ending June. The FDA...
Eli Lilly Faces US Probe Over China Trials, Shifts Cancer Drug Rights
The U.S. House Select Committee on the Chinese Communist Party is investigating Eli Lilly’s clinical trial activities in China. This bipartisan probe focuses...